Pancreatic Cancer Competitive Landscape Report 2023 (Updated)

DelveInsight's, "Pancreatic Cancer Competitive landscape 2023" report provides comprehensive insights about 250+ Pancreatic Cancer Companies and 300+ drugs in Pancreatic Cancer Competitive landscape. It covers the Pancreatic Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Pancreatic Cancer Competitive Landscape Report
• DelveInsight's Pancreatic Cancer report depicts a robust space with 250+ Pancreatic Cancer companies working to develop 300+ pipeline therapies for Pancreatic Cancer treatment.
• The leading Pancreatic Cancer Companies working in the market include Panbela Therapeutics, ERYtech Pharma, Jiangsu HengRui Medicine Co., Ltd., FibroGen, Novartis AG, AB Science, TME Pharma AG, Intensity Therapeutics, Silenseed Ltd, SynerGene Therapeutics, Elevation oncology, Salspera LLC, Redx Pharma Plc, AIM ImmunoTech Inc., Rain Oncology, Jazz Pharmaceuticals, Invyte Corporation, Immodulon Therapeutics Ltd, GSK plc, Merck Sharp & Dohme LLC, Roche, Helsinn Healthcare SA, Argenus Inc., Actuate Therapeutics, OSE Immunotherapeutics, Incyte Corporation, Galera Therapeutics, CSPC ZhongQi Pharmaceutical Technology, Astellas Pharma Global Development, Inc., NanOlogy, Theriva Biologics, AstraZeneca, Berg LLC, Agenus, ABVC BioPharma, Inc., Boehringer Ingelheim, Alligator Bioscience, CARsgenTherapeutics Co. Ltd, Purple Biotech Ltd., Lisata Therapeutics, Chongqing Precision Biotech Co., Ltd, Cybrexa Therapeutics, Bold Therapeutics, BioNTech SE, Bristol-Myers Squibb, DEKA Biosciences, Senhwa Biosciences, Cue Biopharma, Carisma Therapeutics Inc., and others.
• Promising Pancreatic Cancer therapies in the various stages of development include Gemcitabine plus TS-1, Pegilodecakin, FOLFOX, Nanoplatin (NC-6004) and Gemcitabine, RP72, Demcizumab, Abraxane®, ACP-196, and others.
• December 2023: Processa Pharmaceuticals announced a study of Phase 1 clinical trials for RX-3117. This will be a Phase 1b/2a multicenter 2-stage study. Phase 1 will be conducted as a dose-finding, open-label study of oral RX-3117 administered in combination with Abraxane® to subjects with metastatic pancreatic cancer. After completion of the Phase 1 portion, a Phase 2a study will be conducted using a 2 stage, open-label design, of RX 3117 and Abraxane® in combination to treat subjects with metastatic pancreatic cancer as first line therapy.
• December 2023: Takara Bio Inc. announced a study of Phase 1 clinical trials for TBI-1401(HF10), Gemcitabine, Nab-paclitaxel and TS-1. The purpose of this study is to determine the recommended dose of TBI-1401(HF10) treatment in combination with chemotherapy (Gemcitabine + Nab-paclitaxel or TS-1) in patients with stage III or IV unresectable pancreatic cancer.

Request a sample and discover the recent advances in Pancreatic Cancer Drugs @ Pancreatic Cancer Competitive Landscape Report- https://www.delveinsight.com/sample-request/pancreatic-cancer-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

The Pancreatic Cancer report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition - deals values trends. The sub-segmentation is described in the Pancreatic Cancer report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.

Pancreatic Cancer Overview
Pancreatic cancer is a disease in which malignant or cancer cells form in the tissues of the pancreas. Pancreatic cancer begins in the tissues of the pancreas - an organ in the abdomen that lies behind the lower part of the stomach. Pancreatic cancer most frequently arises from pancreatic intraepithelial neoplasia (PanIN), the classic pre-neoplastic lesions, but can also arise from larger precursor lesions, namely, intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic neoplasms.

Find out more about Pancreatic Cancer Analytical Perspective: In-depth Commercial Assessment @ Pancreatic Cancer Collaboration Analysis by Companies- https://www.delveinsight.com/sample-request/pancreatic-cancer-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Pancreatic Cancer Companies and Therapies
• Novartis AG: NIS793
• AB Science: Masitinib
• Panbela Therapeutics: SBP-101
• Intensity Therapeutics: INT230-6
• TME Pharma AG: Olaptesed Pegol

Pancreatic Cancer Competitive Landscape: Analytical Perspective
The Pancreatic Cancer report comprises of comparative assessment of Companies (by therapy, development stage, and technology).

Pancreatic Cancer Report Assessment
• Pancreatic Cancer Company Analysis
• Pancreatic Cancer Therapeutic Assessment
• Pancreatic Cancer Pipeline Assessment
• Inactive Pancreatic Cancer Drugs Assessment
• Pancreatic Cancer Unmet Needs

Learn more about the emerging Pancreatic Cancer Competitive Landscape @ Pancreatic Cancer Market Drivers and Barriers, Unmet Needs- https://www.delveinsight.com/sample-request/pancreatic-cancer-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Pancreatic Cancer Report
• Coverage- Global
• Pancreatic Cancer Companies- Panbela Therapeutics, ERYtech Pharma, Jiangsu HengRui Medicine Co., Ltd., FibroGen, Novartis AG, AB Science, TME Pharma AG, Intensity Therapeutics, Silenseed Ltd, SynerGene Therapeutics, Elevation oncology, Salspera LLC, Redx Pharma Plc, AIM ImmunoTech Inc., Rain Oncology, Jazz Pharmaceuticals, Invyte Corporation, Immodulon Therapeutics Ltd, GSK plc, Merck Sharp & Dohme LLC, Roche, Helsinn Healthcare SA, Argenus Inc., Actuate Therapeutics, OSE Immunotherapeutics, Incyte Corporation, Galera Therapeutics, CSPC ZhongQi Pharmaceutical Technology, Astellas Pharma Global Development, Inc., NanOlogy, Theriva Biologics, AstraZeneca, Berg LLC, Agenus, ABVC BioPharma, Inc., Boehringer Ingelheim, Alligator Bioscience, CARsgenTherapeutics Co. Ltd, Purple Biotech Ltd., Lisata Therapeutics, Chongqing Precision Biotech Co., Ltd, Cybrexa Therapeutics, Bold Therapeutics, BioNTech SE, Bristol-Myers Squibb, DEKA Biosciences, Senhwa Biosciences, Cue Biopharma, Carisma Therapeutics Inc., and others.
• Pancreatic Cancer therapies- Gemcitabine plus TS-1, Pegilodecakin, FOLFOX, Nanoplatin (NC-6004) and Gemcitabine, RP72, Demcizumab, Abraxane®, ACP-196, and others.
• Pancreatic Cancer Therapeutics Assessment- Product Type, Stage and Product Type, Route of Administration, Stage and Route of Administration, Molecule Type, Stage and Molecule Type

Dive deep into rich insights for new drugs for Pancreatic Cancer Product Developmental Activities, Visit @ Pancreatic Cancer Research and Development Activities- https://www.delveinsight.com/sample-request/pancreatic-cancer-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Pancreatic Cancer: Overview
4. Pancreatic Cancer-Analytical Perspective: In-depth Commercial Assessment
5. Pancreatic Cancer Competitive Landscape
6. Pancreatic Cancer Therapeutic Assessment
7. Pancreatic Cancer: Company and Product Profiles (Marketed Therapies)
8. Merck Sharp & Dohme LLC
9. Keytruda (pembrolizumab)
10. Pancreatic Cancer: Company and Product Profiles (Pipeline Therapies)
11. Late Stage Products (Phase III)
12. Novartis AG
13. NIS793
14. Drug profiles in the detailed report…..
15. Mid-Stage Products (Phase II)
16. AB Science
17. Masitinib
18. Drug profiles in the detailed report…..
19. Early Stage Products (Phase I)
20. Carisma Therapeutics Inc.
21. CT-0508
22. Drug profiles in the detailed report…..
23. Preclinical and Discovery Stage Products
24. TILT Biotherapeutics LLC
25. TILT-452
26. Drug profiles in the detailed report…..
27. Inactive Products
28. Pancreatic Cancer Unmet needs
29. Pancreatic Cancer Market drivers and barriers
30. Appendix

For further information on the Pancreatic Cancer Report @ Pancreatic Cancer Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/pancreatic-cancer-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

List of Important Links-

https://forum.omz-software.com/user/germandennydones
https://bootstrapbay.com/user/germandennydones
https://freeline.mn.co/posts/51448756
https://socialmediainuk.com/story16816595/hemophilia-market-size
https://opensocialfactory.com/story15972624/hemophilia-a-market-forecast
https://ztndz.com/story18555072/hemophilia-a-market-outlook
https://gorillasocialwork.com/story17082192/hemophilia-a-market-trends
https://socialrus.com/story16299031/hemophilia-a-market-size
https://socialmediastore.net/story16857930/hemophilia-a-market-outlook
https://bookmarksurl.com/story2025609/hemophilia-a-market-size
https://myeasybookmarks.com/story2080208/pulmonary-arterial-hypertension-market-size
https://skillcrush.mn.co/posts/51450760
https://derpyshare.mn.co/posts/51450900
https://hocplayground.mn.co/posts/51451004
https://chatclub.mn.co/posts/51451178
https://printable-calendar.mn.co/posts/51451354
https://shangwich.mn.co/posts/51451496
https://drujrake.mn.co/posts/51451820
https://healingtheinnerme.mn.co/posts/51452145
https://mydreamangels.mn.co/posts/51452294

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services

This release was published on openPR.